Role of known molecular markers of resistance in the antimalarial potency of piperaquine and dihydroartemisinin in vitro

• Main Authors: Sant Muangnoicharoen, David J. Johnson, Sornchai Looareesuwan, Srivicha Krudsood, Stephen A. Ward
• Other Authors: Liverpool School of Tropical Medicine
• Format: Article
• Published: 2018
• Subjects: Medicine; Pharmacology, Toxicology and Pharmaceutics
• Online Access: https://repository.li.mahidol.ac.th/handle/123456789/28125
• Institution: Mahidol University

Using a range of laboratory-adapted and genetically modified Plasmodium falciparum parasite isolates, we investigated the interaction between dihydroartemisinin and piperaquine (PIP), the individual components of an artemisinin combination therapy currently under development, in addition to the role of known drug resistance genes in parasite susceptibility in vitro. All but one parasite line investigated displayed an interaction of dihydroartemisinin and PIP that was antagonistic, although the degree of antagonism was isolate dependent. In terms of resistance markers, the pfcrt haplotypes CVIET and SVMNT were positively associated with reduced sensitivity to PIP, with parasites carrying the South American CQR (SVMNT) allele being generally less sensitive than CVIET parasites. Parasites carrying the CQS (CVMNK) allele displayed a further increase in PIP sensitivity compared with CVIET and SVMNT parasites. Our data indicate that PIP sensitivity was not affected by pfmdrl sequence status, despite positive correlations between the structurally related compound amodlaqulne and pfmdrl mutations In other studies. In contrast, neither the pfcrt nor pfmdrl sequence status had any significant impact on susceptibility to dihydroartemisinin. Copyright © 2009, American Society for Microbiology. All Rights Reserved.